Cytotoxic T lymphocytes and NK cells play an important role in eliminating malignant tumor
cells and the number and activity of tumor-infiltrating T cells represent a good marker for …

Over the last two decades, the outcomes for patients with multiple myeloma, a plasma cell
malignancy, have dramatically improved. The development of the immunomodulatory drugs …

In historical attempts to treat morning sickness, use of the drug thalidomide led to the birth of
thousands of children with severe birth defects. Despite their teratogenicity, thalidomide and …

Tumor-derived lactic acid inhibits T and natural killer (NK) cell function and, thereby, tumor
immunosurveillance. Here, we report that melanoma patients with high expression of …

Multiple myeloma (MM), a hematologic malignancy that preferentially colonizes the bone
marrow, remains incurable with a survival rate of 3 to 6 mo for those with advanced disease …

For decades, anticancer targeted therapies have been designed to inhibit kinases or other
enzyme classes and have profoundly benefited many patients. However, novel approaches …

Clinical progress in multiple myeloma (MM), an incurable plasma cell (PC) neoplasia, has
been driven by therapies that have limited applications beyond MM/PC neoplasias and do …

Currently, a marked number of clinical trials on cancer treatment have revealed the success
of immunomodulatory therapies based on immune checkpoint inhibitors that activate tumor …

Cereblon (CRBN) is a primary target of thalidomide and mediates its multiple
pharmacological activities, including teratogenic and antimyeloma activities. CRBN …

Background: Multiple myeloma is the second most common hematologic malignancy, which
to date remains incurable despite advances in treatment strategies including the use of …